Suraksha Diagnostic growth ratios

Per cent unless marked ×
Tap a line for its trendFY26Mar 2026
+23.1%
+17.4%
+17.4%
+1.4%
+3.5%
+34.4%
+15.8%
+29.2%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

SURAKSHA₹300.45

Suraksha Diagnostic Limited

· Pharma & Health
₹ CrorePeersKRSNAAHEALTHXNEPHROPLUS3BBLACKBIOMcap ₹1,565 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—+23.1—
EBITDA Growth—+17.4—
EBIT Growth—+17.4—
Net Income Growth—+1.4—
EPS Growth—+3.5—
Total Assets Growth—+34.4—
Total Equity Growth—+15.8—
Cash from Operations Growth—+29.2—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.